| Pills for Dry AMD-Acucela-Recruiting |
 |
 |
|
 Share
The ENVISION Clarity Trial, a Phase II clinical trial, is underway to study an oral medication for geographic atrophy (GA) in dry AMD. Currently known as ACU-4429, the pill is being tested in several different dosages, to determine its safety and tolerability.
Patients are being recruited to participate in a randomized, double-masked, placebo-controlled study, taking place at sites throughout the U.S.. Participants receive either an active ACU-4429 in one of several doses, or a placebo pill. To be eligible, subjects must have geographic atrophy from dry AMD and meet other criteria.
ACU-4429, a visual cycle modulator, appears to decrease the toxic by-products that have been shown to play a role in dry AMD. It has been granted FDA Fast Track status, which is designed to facilitate the development and expedite the review of new drugs with the potential to address unmet medical needs. For more information, visit ClinicalTrials.gov. |
Search
Get News!
SIGN UP NOW
To receive the "AMD Update" and keep up-to-date with the latest research & treatment options:
For Email Newsletters you can trust